Top Cannabis Companies Strengthen Financial Footing Heading Into 2026

As global cannabis policy continues to evolve, major cannabis companies are reinforcing their financial footing, kicking off 2026 with balance-sheet repairs, steady revenue growth, and renewed positioning for potential regulatory change.

Canopy Growth Strengthens Balance Sheet With Debt Refinancing

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) announced this week that it has refinanced its debt, pushing repayment obligations out to 2031 while raising fresh capital, lowering interest costs, and strengthening its balance sheet to support long-term priorities.

The Canadian cannabis giant said the transactions will secure approximately CA$425 million ($306.2 million) in cash on hand following the completion of a series of financings, including a new $150 million term loan led by JGB Management Inc..

Canopy said it plans to use the proceeds to repay $101 million in existing debt due in 2027, fund day-to-day operations, and support future acquisitions. The move provides greater financial flexibility as the company works to integrate MTL Cannabis Corp, expand its European medical cannabis business, and pursue adjusted EBITDA profitability.

“As we continue to execute our strategy focused on disciplined growth, operational excellence, and financial stewardship, these transactions enable the strategic scaling necessary to reinforce Canopy Growth’s leadership position, support growing demand in the European medical market, and advance our path to sustained adjusted EBITDA profitability,” said Luc Mongeau, CEO of Canopy Growth.

Tilray Brands Q2 Revenue Up 3% YoY, Cash Position Improves Despite Lower Gross Profit

Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) reported a 3% year-over-year increase in net revenue to $217.5 million for the quarter, driven in part by continued international expansion.

International medical cannabis sales rose 36% year over year, while the company transitioned from a net debt position to net cash of approximately $27 million, ending the quarter with $292 million in cash and marketable securities.

Gross profit declined to $57.5 million, down from $61.2 million in the prior-year period, while the company’s net loss narrowed significantly to $43.5 million, compared with $85.3 million a year earlier.

Management said it continues to position Tilray to capitalize on potential federal cannabis rescheduling in the U.S., with plans to leverage its existing pharmaceutical infrastructure to expand its medical cannabis platform.

SNDL Completes Initial Closing in Two-Stage Cannabis Retail Deal

SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) and 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) announced last week that they have completed the initial closing of a previously disclosed retail acquisition involving cannabis stores in Alberta and Saskatchewan.

Under the original agreement announced April 9, 2025, SNDL agreed to acquire 32 Cost Cannabis and T Cannabis retail stores across Ontario, Alberta, and Saskatchewan for $32.2 million in cash. The transaction was structured into two separate closings due to regulatory approval requirements.

A revised agreement dated Dec. 15, 2025, established a $5 million first closing covering five stores in Alberta and Saskatchewan, including a $2 million non-refundable deposit already paid. The remaining $27.2 million second closing—covering 27 stores in Ontario—had its outside date extended from Dec. 31, 2025, to May 31, 2026.

As previously announced, the second closing is expected to occur during the first half of 2026, subject to receipt of all required regulatory approvals.